PHARMNOVO

pharmnovo-logo

PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe.

#SimilarOrganizations #People #Financial #Website #More

PHARMNOVO

Social Links:

Industry:
Health Care Pharmaceutical

Founded:
2008-01-01

Address:
Lund, Skane Lan, Sweden

Country:
Sweden

Website Url:
http://www.pharmnovo.com

Total Employee:
11+

Status:
Active

Contact:
+46 (0)705 44 32 50

Email Addresses:
[email protected]

Total Funding:
9.92 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Apache Euro Smart App Banner Embedly Nextcloud


Similar Organizations

braeburn-logo

Braeburn

Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.

enbiotix-logo

EnBiotix

EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.

zai-lab-logo

Zai Lab

Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.


Current Advisors List

not_available_image

Gรถran Lerenius Board Member @ PharmNovo
Board_member

Current Employees Featured

per-von-mentzer_image

Per von Mentzer
Per von Mentzer Chief Executive Officer @ PharmNovo
Chief Executive Officer
2020-05-01

david-kendall_image

David Kendall
David Kendall Chief Scientific Officer @ PharmNovo
Chief Scientific Officer

bengt-mentzer_image

Bengt Mentzer
Bengt Mentzer Founder and Chief scientific advisor @ PharmNovo
Founder and Chief scientific advisor
2007-11-01

Founder


bengt-mentzer_image

Bengt Mentzer

Investors List

sciety_image

Sciety

Sciety investment in Series A - PharmNovo

sciety_image

Sciety

Sciety investment in Venture Round - PharmNovo

karolinska_image

Karolinska

Karolinska investment in Venture Round - PharmNovo

almi-invest_image

Almi Invest

Almi Invest investment in Venture Round - PharmNovo

polynom-ab_image

Polynom Investment

Polynom Investment investment in Venture Round - PharmNovo

sciety_image

Sciety

Sciety investment in Series A - PharmNovo

Official Site Inspections

http://www.pharmnovo.com Semrush global rank: 6.08 M Semrush visits lastest month: 1.34 K

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 75.2.70.75
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "PharmNovo"

PharmNovo - Crunchbase Company Profile & Funding

PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different โ€ฆSee details»

For investors | PharmNovo

The opportunity. PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for neuropathic pain, a condition currently lacking effective and safe โ€ฆSee details»

PharmNovo - Funding, Financials, Valuation & Investors

PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe. ... How much funding has this organization โ€ฆSee details»

Search for chronic pain treatment initiated 2008

Focusing on chronic pain. PharmNovo was founded in 2008 by the international medical researcher Bengt von Mentzer after 27 years as a drug discovery group leader for Astra Zeneca.. Finding a safe and effective way to help patients โ€ฆSee details»

PharmNovo 2025 Company Profile: Valuation, Funding โ€ฆ

PharmNovo General Information Description. Developer of nerve pain drugs and therapies intended to discover safe and effective drugs to make lives better. โ€ฆSee details»

About PharmNovo - pharmiweb.jobs

5 days ago PharmNovo AB is a Swedish clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack โ€ฆSee details»

PharmNovo - 2025 Company Profile, Funding & Competitors

Mar 13, 2025 PharmNovo. has raised a total funding of $20.9M over 4 rounds. Its first funding round was on Nov 04, 2020. What are the most recent funding rounds of PharmNovo? Its โ€ฆSee details»

Get in Touch - PharmNovo

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one โ€ฆSee details»

PharmNovo - Products, Competitors, Financials, Employees, โ€ฆ

PharmNovo receives positiv FDA feedback Photo: PharmNovo The company has received positive and constructive feedback for its lead drug product PN6047, a selective delta opioid โ€ฆSee details»

PharmNovo | LinkedIn

PharmNovo | 704 followers on LinkedIn. Innovation in pain relief | PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for โ€ฆSee details»

PharmNovo's Leadership Team Team - Team members and org โ€ฆ

Other teams at PharmNovo. View all +5. Board of Directors. 8 members. CEO and Executive Team. 2 members. The Org helps you hire great candidates. It takes less than ten minutes to โ€ฆSee details»

Karolinska Development's portfolio company PharmNovo receives โ€ฆ

Mar 12, 2025 PharmNovoโ€™s most advanced drug candidate, PN6047, is a selective delta-opioid receptor agonist (DORA) being developed as a new treatment for complex pain conditions. โ€ฆSee details»

Anthony P D Ford | PharmNovo

Roles in PharmNovo: Business advisor and Director of the board. Born: 1965. Education: Ph.D. Trained in neuropharmacology and holds a Ph.D. from the University of Nottingham (UK). โ€ฆSee details»

Pharmnovo receives positive FDA feedback on PN6047, aims for โ€ฆ

Mar 12, 2025 Pharmnovo has received positive feedback from the FDA on its lead drug candidate PN6047. This is stated in a press release.Pharmnovo is a portfolio company of โ€ฆSee details»

Meet Jarkko Kalliomäki, Chief Medical Officer, PharmNovo

Oct 03, 2023: At the forefront of PharmNovo's journey towards pioneering solutions in pain relief stands Jarkko Kalliomäki, our esteemed Chief Medical Officer since September 2022. With his โ€ฆSee details»

PharmNovo announces positive Phase I results for neuropathic โ€ฆ

Mar 22, 2024 Swedish pharmaceutical company PharmNovo is proud to announce the positive final results from the Phase I trial of its neuropathic pain drug candidate, PN6047. This trial โ€ฆSee details»

Karolinska Development's portfolio company PharmNovo

Mar 12, 2025 PharmNovoโ€™s most advanced drug candidate, PN6047, is a selective delta-opioid receptor agonist (DORA) being developed as a new treatment for complex pain conditions. โ€ฆSee details»

Karolinska Developments portföljbolag PharmNovo erhåller

STOCKHOLM, SVERIGE 12 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget PharmNovo erhöll positiv återkoppling rörande bolagets längst โ€ฆSee details»

Carl-Magnus Andersson | PharmNovo

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break โ€ฆSee details»

JPET approves PN6047 - PharmNovo

Oct 9, 2019 PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with โ€ฆSee details»

linkstock.net © 2022. All rights reserved